Biolinerx Announces Oral Presentation on Data from Phase 1 Clinical Trial Evaluating Motixafortide for Cd34 Hematopoietic Stem Cell Mobilization for Gene Therapies in Sickle Cell Disease At Ash 2024
Biolinerx Announces Oral Presentation on Data from Phase 1 Clinical Trial Evaluating Motixafortide for Cd34 Hematopoietic Stem Cell Mobilization for Gene Therapies in Sickle Cell Disease At Ash 2024
Nov 5, 2024
marketscreener.com
Bioline annonce qu'une étude pilote sur une combinaison de médicaments potentiels contre le cancer du pancréas montre une amélioration du taux de réponse global ; les actions s'envolent avant l'ouverture de la bourse
Bioline annonce qu'une étude pilote sur une combinaison de médicaments potentiels contre le cancer du pancréas montre une amélioration du taux de réponse global ; les actions s'envolent avant l'ouverture de la bourse
11 months ago
zonebourse.com
2025-05-30 07:10:00 BLRX Level 2 and Time & Sales
5:12
2025-05-30 07:10:00 BLRX Level 2 and Time & Sales
1 views4 days ago
YouTubeLinas K
BioLineRx Ltd BLRX Q3 2025 Earnings Call
24:36
BioLineRx Ltd BLRX Q3 2025 Earnings Call
6 views4 months ago
YouTubeFyfull
BioLineRx: Hidden Gem or Value Trap? | BLRX 2025 Deep Dive
13:36
BioLineRx: Hidden Gem or Value Trap? | BLRX 2025 Deep Dive
36 views1 month ago
YouTubeIron_Financial
BioLineRx | Discover Our Pipeline
BioLineRx | Discover Our Pipeline
Jun 13, 2019
biolinerx.com
Cramer: This biotech stock could be worth over $100 billion on an FDA approval
5:19
Cramer: This biotech stock could be worth over $100 billion on an FDA approval
427.5K viewsOct 30, 2019
YouTubeCNBC Television
0:44
ANL News: Adlai Nortye Ltd. (NASDAQ:ANL) - A Promising Investment in Biotechnology
77 views3 months ago
YouTubeValuezAi
3:16
The Most Anticipated Earnings Releases for the Week of March 23, 2026
353 views1 month ago
YouTubeEarnings Whispers
News for BLRX
5 months ago
zacks.com
See more